Scientific deep-dive

A Weight Drug for Having Too Little Fat

Lipodystrophy is the opposite of obesity: people are missing fat tissue, and are severely metabolically ill because of it. In a cohort given tirzepatide, those with familial partial lipodystrophy cut their daily insulin by a median of 109 units.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

Lipodystrophy is the opposite of obesity: people with it are missing fat tissue, partially or almost entirely. (It is easily confused with lipedema, which is too much fat in the legs.) They also have some of the most severe metabolic disease in medicine, and the missing fat is what causes it. In a cohort of 17 such patients given tirzepatide, the 14 with familial partial lipodystrophy saw their daily insulin requirement fall by a median of 109 units.[1]

Why too little fat causes metabolic disease

Fat tissue is safe storage. Its job is to hold lipid somewhere it does no harm. When there is not enough of it, through inherited partial lipodystrophy or generalized forms where fat is nearly absent, the lipid has to go somewhere else.

It goes into the liver, into muscle, into the bloodstream. The result is extreme insulin resistance, triglycerides that can reach thousands, fatty liver disease and diabetes, in people who are frequently lean.

The problem is not too much lipid in the body. It is too little room for it.

That is why giving a weight-loss drug here is less strange than it sounds. The aim is to reduce the lipid load that inadequate tissue is being asked to handle, rather than to remove fat from someone who has too little.

What happened

Seventeen patients receiving tirzepatide in ordinary clinical care were tracked within natural history studies. Of these, 14 had familial partial lipodystrophy (aged 30 to 74, mostly women) and three had rarer forms. The measured results below come from the 14, followed for a median of 8.7 months.

Median change in the 14 patients with familial partial lipodystrophy, with the full observed range.[1]
MeasureMedian changeRangeP
HbA1c−1.1%−6.3% to −0.1%< 0.001
Insulin requirement−109 units/day−315 to 00.002
Triglycerides−65 mg/dL−3,820 to +430.003
BMI−1.7 kg/m²−5.9 to +0.90.008

Read the ranges rather than the medians. A triglyceride fall of 3,820 mg/dL means someone arrived with a level in the thousands, where the immediate risk is acute pancreatitis rather than long-term cardiovascular disease. And a reduction of 315 units of insulin a day describes a degree of insulin resistance most clinicians will never see.

The BMI column carries the other lesson: the range includes a gain. In a group defined by having too little fat, a modest BMI reduction is not obviously the goal, and one patient went the other way while the metabolic measures still moved.

What seventeen patients can and cannot show

This is an observational cohort with no control group. Everyone received the drug, everyone was followed within existing studies, and nothing separates the effect of tirzepatide from changes in other treatment, from regression to the mean in people recruited during poor control, or from the attention that comes with being studied.

For a disease this rare, seventeen patients is a substantial series. Familial partial lipodystrophy affects a few people per million, and a randomized trial in it may never be run. That is a good reason to take a case series more seriously here than one would for common obesity.

It is also a small series: the medians come from fourteen people followed for a median of roughly nine months, and the authors title their own paper with a question mark.

Why it is worth knowing about

  • It separates two things these drugs do. Removing fat and reducing lipid load are not the same, and this population makes the distinction visible.
  • It is a reminder that body weight is a poor proxy for metabolic health. These patients are often lean and profoundly metabolically ill, which makes the same point as beyond BMI from the other direction.
  • Side effects were the ordinary ones. The report describes them as benign gastrointestinal symptoms, with nothing specific to the condition.
  • It is off-label, in a rare disease, on a case series. That is how treatment for rare diseases usually begins.

Frequently Asked Questions

A group of rare disorders in which fat tissue is partially or almost entirely absent. Because fat is where the body safely stores lipid, its absence forces lipid into the liver, muscle and bloodstream, producing extreme insulin resistance, very high triglycerides and diabetes in people who are often lean.
The aim is not to remove fat but to reduce the lipid load that inadequate fat tissue is being asked to handle. It is a different purpose for the same molecule.
In the 14 patients with familial partial lipodystrophy, over a median of 8.7 months, HbA1c fell by a median of 1.1%, daily insulin requirement by 109 units, triglycerides by 65 mg/dL and BMI by 1.7. The ranges are more striking than the medians: one triglyceride fall reached 3,820 mg/dL and one insulin reduction reached 315 units a day.
It is an observational cohort of 17 people with no control group. For a disease affecting a few people per million, where a randomized trial may never be run, a series this size carries more weight than it would in common obesity. It is still 17 people, and the measured results come from the 14 with familial partial lipodystrophy, followed for a median of about nine months.
The report describes them as benign gastrointestinal symptoms, with nothing specific to lipodystrophy.

References

  1. 1.Meral R, Celik Guler M, Kaba D, et al. Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option? Diabetes Care. 2025. PMID: 40063619.

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

7.3

Found

People who want clinician visits billed to commercial insurance, with compounded medication in the plan price

From $149/mo + membership

Get started →
Read full review →

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →